These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
271 related articles for article (PubMed ID: 34506622)
1. Sequential Development of JAK2V617F Mutation and BCR-ABL1 Fusion in Individual Patients With Myeloproliferative Neoplasms. Zhao Y; Reddi D; McCracken J; Iranzad N; Rehder C; Neff J; Wang E Arch Pathol Lab Med; 2022 Jun; 146(6):710-717. PubMed ID: 34506622 [TBL] [Abstract][Full Text] [Related]
2. Rare Case of Accelerated-Phase Chronic Myeloid Leukemia Diagnosed During Treatment for JAK2 V617F-Positive Primary Myelofibrosis. Ryu J; Chu D; Park B; Kim M; Cho YU; Hwang SH; Jang S; Seo EJ; Lee JH; Park CJ Lab Med; 2022 Nov; 53(6):e140-e144. PubMed ID: 35243502 [TBL] [Abstract][Full Text] [Related]
3. Myeloproliferative neoplasms with concurrent BCR-ABL1 translocation and JAK2 V617F mutation: a multi-institutional study from the bone marrow pathology group. Soderquist CR; Ewalt MD; Czuchlewski DR; Geyer JT; Rogers HJ; Hsi ED; Wang SA; Bueso-Ramos CE; Orazi A; Arber DA; Hexner EO; Babushok DV; Bagg A Mod Pathol; 2018 May; 31(5):690-704. PubMed ID: 29327708 [TBL] [Abstract][Full Text] [Related]
4. A case of double positive myeloproliferative neoplasm: A diagnostic and therapeutic challenge. Shaikh AB; Aribandi A; Gupta A; Subramanian SK; Goyal M Indian J Pathol Microbiol; 2021; 64(4):820-823. PubMed ID: 34673614 [TBL] [Abstract][Full Text] [Related]
5. BCR-ABL1-positive CML and BCR-ABL1-negative chronic myeloproliferative disorders: some common and contrasting features. Cross NC; Daley GQ; Green AR; Hughes TP; Jamieson C; Manley P; Mughal T; Perrotti D; Radich J; Skoda R; Soverini S; Vainchenker W; Verstovsek S; Villeval JL; Goldman JM Leukemia; 2008 Nov; 22(11):1975-89. PubMed ID: 19002192 [No Abstract] [Full Text] [Related]
6. Colony-Forming Cell Assay Detecting the Co-Expression of JAK2V617F and BCR-ABL1 in the Same Clone: A Case Report. Tirrò E; Stella S; Massimino M; Zammit V; Pennisi MS; Vitale SR; Romano C; Di Gregorio S; Puma A; Di Raimondo F; Stagno F; Manzella L Acta Haematol; 2019; 141(4):261-267. PubMed ID: 30965317 [TBL] [Abstract][Full Text] [Related]
7. Successful Treatment of a Patient with Chronic Myelogenous Leukemia with Concurrent Janus Kinase 2 (JAK2) R795S Mutation and Breakpoint Cluster Region-ABL1 (BCR-ABL1) Fusion: A Case Report and Literature Review. Yue Y; Wei W; Guo Y; Wang F; Dong W; Liu Y; Lin Y; Cao Y; Gu W Am J Case Rep; 2020 Oct; 21():e925151. PubMed ID: 33021971 [TBL] [Abstract][Full Text] [Related]
8. Co-existence of Frikha R; Turki F; Kassar O; Elloumi M; Kamoun H J Oncol Pharm Pract; 2021 Oct; 27(7):1784-1789. PubMed ID: 33567976 [TBL] [Abstract][Full Text] [Related]
9. Concomitant BCR-ABL1 translocation and JAK2(V617F) mutation in three patients with myeloproliferative neoplasms. Hummel JM; Kletecka MC; Sanks JK; Chiselite MD; Roulston D; Smith LB; Czuchlewski DR; Elenitoba-Johnson KS; Lim MS Diagn Mol Pathol; 2012 Sep; 21(3):176-83. PubMed ID: 22847163 [TBL] [Abstract][Full Text] [Related]
10. Is there a role for JAK inhibitors in BCR-ABL1-negative myeloproliferative neoplasms other than myelofibrosis? Pardanani A; Tefferi A Leuk Lymphoma; 2014 Dec; 55(12):2706-11. PubMed ID: 25520049 [TBL] [Abstract][Full Text] [Related]
11. The concomitant occurrence of JAK2V617F mutation and BCR/ABL transcript with phenotypic expression - an overlapping myeloproliferative disorder or two distinct diseases? - case report. Ursuleac I; Colita A; Adam T; Jardan C; Ilea A; Coriu D J Med Life; 2013 Mar; 6(1):34-7. PubMed ID: 23599815 [TBL] [Abstract][Full Text] [Related]
13. Molecular genetic tests for JAK2V617F, Exon12_JAK2 and MPLW515K/L are highly informative in the evaluation of patients suspected to have BCR-ABL1-negative myeloproliferative neoplasms. dos Santos MT; Mitne-Neto M; Miyashiro K; Chauffaille Mde L; Rizzatti EG J Clin Pathol; 2014 Feb; 67(2):176-8. PubMed ID: 23986553 [TBL] [Abstract][Full Text] [Related]
14. Myeloid neoplasms with concurrent BCR-ABL1 and CBFB rearrangements: A series of 10 cases of a clinically aggressive neoplasm. Salem A; Loghavi S; Tang G; Huh YO; Jabbour EJ; Kantarjian H; Wang W; Hu S; Luthra R; Medeiros LJ; Khoury JD Am J Hematol; 2017 Jun; 92(6):520-528. PubMed ID: 28253536 [TBL] [Abstract][Full Text] [Related]
15. CALR, JAK2 and MPL mutation status in Argentinean patients with BCR-ABL1- negative myeloproliferative neoplasms. Ojeda MJ; Bragós IM; Calvo KL; Williams GM; Carbonell MM; Pratti AF Hematology; 2018 May; 23(4):208-211. PubMed ID: 28990497 [TBL] [Abstract][Full Text] [Related]
16. Hematopoietic stem cells, progenitor cells and leukemic stem cells in adult myeloproliferative neoplasms. Ng AP Leuk Lymphoma; 2013 May; 54(5):922-33. PubMed ID: 23013358 [TBL] [Abstract][Full Text] [Related]
17. Emergence of chronic myelogenous leukemia from a background of myeloproliferative disorder: JAK2V617F as a potential risk factor for BCR-ABL translocation. Pingali SR; Mathiason MA; Lovrich SD; Go RS Clin Lymphoma Myeloma; 2009 Oct; 9(5):E25-9. PubMed ID: 19858050 [TBL] [Abstract][Full Text] [Related]
18. BCR-ABL1--negative myeloproliferative neoplasms: a review of molecular biology, diagnosis, and treatment. Vakil E; Tefferi A Clin Lymphoma Myeloma Leuk; 2011 Jun; 11 Suppl 1():S37-45. PubMed ID: 22035746 [TBL] [Abstract][Full Text] [Related]